Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary end point was progression-free survival (PFS); secondary end point was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6–18.8), and TTD was 18.46 months (95% CI: 9.54–27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Raez LE, Cardona AF, Santos ES et al. The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer 119, 7–13 (2018).
MedlineGoogle Scholar
2. Raez LE, Santos ES, Rolfo C et al. Challenges in facing the lung cancer epidemic and treating advanced disease in Latin America. Clin. Lung Cancer 18(1), e71–e79 (2017).
MedlineGoogle Scholar
3. Corrales-Rodríguez L, Arrieta O, Mas L et al. An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer 113, 30–36 (2017).
MedlineGoogle Scholar
4. Sotelo-Rodríguez DC, Ruíz-Patiño A, Ricaurte L et al. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience 13, 936 (2019).
MedlineGoogle Scholar
5. Arrieta O, Cardona AF, Bramuglia G et al. Molecular epidemiology of ALK rearrangements in advanced lung adenocarcinoma in Latin America. Oncology 96(4), 207–216 (2019).
Medline CASGoogle Scholar
6. Solomon BJ, Kim DW, Wu YL et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J. Clin. Oncol. 36(22), 2251–2258 (2018).
Medline CASGoogle Scholar
7. Planchard D, Popat S, Kerr K et al. Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol. 30(5), 863–870 (2019).
Medline CASGoogle Scholar
8. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 12(7), 429–439 (2014).
MedlineGoogle Scholar
9. Cadranel J, Park K, Arrieta O et al. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: a chart review study. Lung Cancer 98, 9–14 (2016).
MedlineGoogle Scholar
10. Costa DB, Shaw AT, Ou SH et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 33(17), 1881–1888 (2015).
Medline CASGoogle Scholar
11. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4(120), 120ra17 (2012).
MedlineGoogle Scholar
12. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472–1482 (2012).
Medline CASGoogle Scholar
13. Camidge DR, Dziadziuszko R, Peters S et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global Phase III ALEX study. J. Thorac. Oncol. 14(7), 1233–1243 (2019).
Medline CASGoogle Scholar
14. Soria JC, Tan DSW, Chiari R et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389(10072), 917–929 (2017).
Medline CASGoogle Scholar
15. Shaw AT, Kim TM, Crino L et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 18(7), 874–886 (2017).
Medline CASGoogle Scholar
16. Camidge DR, Kim HR, Ahn MJ et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2027–2039 (2018). • A phase 3 trial demonstrated the superiority of brigatinib in terms of PFS and ORR compared with crizotinib in advanced ALK-positive NSCLC who had not previously received ALK inhibitors.
Medline CASGoogle Scholar
17. Camidge DR, Kim DW, Tiseo M et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J. Clin. Oncol. 36(26), 2693–2701 (2018). • Exploratory analysis confirmed an intracranial response of 67% and a median intracranial progression-free survival of 18.4 months with brigatinib.
Medline CASGoogle Scholar
18. Solomon BJ, Besse B, Bauer TM et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19(12), 1654–1667 (2018).
Medline CASGoogle Scholar
19. Gainor JF, Dardaei L, Yoda S et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6(10), 1118–1133 (2016).
Medline CASGoogle Scholar
20. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 7(2), 137–155 (2017).
Medline CASGoogle Scholar
21. Zhang S, Anjum R, Squillace R et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin. Cancer Res. 22(22), 5527–5538 (2016).
Medline CASGoogle Scholar
22. Arrieta O, Carmona A, Ramírez-Tirado LA et al. Survival of patients with advanced non-small cell lung cancer enrolled in clinical trials. Oncology 91(4), 185–193 (2016).
MedlineGoogle Scholar
23. Martín C, Cardona AF, Zatarain-Barrón ZL et al. Real-world treatment patterns, survival, and prediction of CNS progression in ALK-positive non-small-cell lung cancer patients treated with first-line crizotinib in Latin America oncology practices. Oncology 94(5), 297–305 (2018).
Medline CASGoogle Scholar
24. Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2018).
Medline CASGoogle Scholar
25. Gerson R, Zatarain-Barrón ZL, Blanco C, Arrieta O. Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system. Salud Publica Mex. 61(3), 352–358 (2019).
MedlineGoogle Scholar
26. Barrón-Barrón F, Guzmán-De Alba E, Alatorre-Alexander J et al. [National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version]. Salud Publica Mex. 61(3), 359–414 (2019).
MedlineGoogle Scholar
27. Cruz-Rico G, Avilés-Salas A, Segura-González M et al. Diagnosis of EML4–ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer. Am. J. Clin. Oncol. 40(6), 631–638 (2017).
Medline CASGoogle Scholar
28. Arrieta O, Zatarain-Barrón ZL, Aldaco F et al. Lung Cancer in Mexico. J. Thorac. Oncol. 14(10), 1695–1700 (2019).
MedlineGoogle Scholar
29. Huber RM, Hansen KH, Paz-Ares Rodriguez L et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA Trial. J. Thorac. Oncol. 15(3), 404–415 (2020).
Medline CASGoogle Scholar
30. Stinchcombe T, Doebele RC, Wang XF et al. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). J. Clin. Oncol. 37(Suppl. 15), 9027- (2019). •• Phase 2 trial that preliminary demonstrated an overall response rate of 40% and a median progression-free survival (PFS) of 6.4 months with brigatinib in heavily pretreated patients after progression to next-generation ALK-TKIs (alectinib, ceritinib).
Google Scholar
31. Lin HM, Pan X, Hou P et al. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program. Future Oncol. 16(15), 1031–1041 (2020). •• Presents real-world evidence supporting brigatinib after next-generation ALK-TKIs, assessing median time to treatment discontinuation after crizotinib (10 months), alectinib (8.7 months), ceritinib (10.3 months) and lorlatinib (7.5 months).
CASGoogle Scholar
32. Sabari JK, Santini FC, Schram AM et al. The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther. 10, 1983–1992 (2017). • Preclinical study that assesses brigatinib activity against resistant mutations dependency on ALK, reporting activity against ALK C1156Y, I1171S/T, V1180L, L1196M, L1152R/P, E1210K and G1269A mutations.
Medline CASGoogle Scholar
33. Katayama R, Friboulet L, Koike S et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20(22), 5686–5696 (2014).
Medline CASGoogle Scholar
34. Descourt R, Perol M, Rousseau-Bussac G et al. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real-world study (BRIGALK study). Lung Cancer 136, 109–114 (2019). •• A retrospective analysis with real-world data that confirmed the efficacy of brigatinib in a cohort of ALK-positive heavily pretreated advanced NSCLC patients; median duration of brigatinib treatment was 6.7, and median PFS was 6.6 months.
MedlineGoogle Scholar
35. Gadgeel SM, Shaw AT, Govindan R et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J. Clin. Oncol. 34(34), 4079–4085 (2016).
Medline CASGoogle Scholar
36. Gandhi L, Ou SI, Shaw AT et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. Eur. J. Cancer 82, 27–33 (2017).
Medline CASGoogle Scholar
37. Zweig JR, Neal JW. Infiltrating the blood-brain barrier in ALK-positive lung cancer. J. Clin. Oncol. 36(26), 2677–2679 (2018).
Medline CASGoogle Scholar
38. Ng TL, Narasimhan N, Gupta N et al. Early-onset pulmonary events associated with brigatinib use in advanced NSCLC. J. Thorac. Oncol. 15(7), 1190–1199 (2020).
Medline CASGoogle Scholar

Vol. 17, No. 2

Metrics

Downloaded 262 times

History

Received 24 July 2020

Accepted 2 September 2020

Published online 28 September 2020

Published in print January 2021

Information

Keywords

Author contributions

Conceptualization: O Arrieta, D Heredia, F Barrón, L Lara-Mejia, AF Cardona, S Campos, J Alatorre; data curation: D Heredia, S Campos, L Martinez-Barrera, J Rodriguez-Cid, J Alatorre, AF Cardona, MA Salinas, D Flores-Estrada; Formal analysis: O Arrieta, D Heredia, F Barrón, S Campos, J Alatorre, J Rodriguez-Cid; Investigation: O Arrieta, D Heredia, F Barrón, AF Cardona, L Lara-Mejia, L Martinez-Barrera, J Rodriguez-Cid; Methodology: O Arrieta, D Heredia, F Barrón, L Lara-Mejia, L Martinez-Barrera, MA Salinas, D Flores-Estrada; project administration: O Arrieta, D Flores-Estrada, AF Cardona, DFE, S Campos, J Alatorre, J Rodriguez-Cid; Resources: O Arrieta, S Campos, J Alatorre, J Rodriguez-Cid; Supervision: O Arrieta, S Campos, J Alatorre, MA Salinas, D Flores-Estrada; writing - draft: O Arrieta, D Heredia, F Barrón, L Lara-Mejia, S Campos, J Alatorre; writing - review and editing: O Arrieta, D Heredia, F Barrón, L Lara-Mejia, S Campos, J Alatorre

Financial & competing interests disclosure

O Arrieta has received honoraria as an advisor, participated in speaker's bureau and given expert opinions to Pfizer, AstraZeneca, Boehringer-Ingelheim, Roche, Lilly and Bristol Myers Squibb. AF Cardona reports grants from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol Myers Squibb and the Foundation for Clinical and Applied Cancer Research (FICMAC); other support from Pfizer, Boehringer Ingelheim, Astra Zeneca, MSD, BMS, Celldex and Roche; personal fees from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly and FICMAC outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Role of the funding source

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Data sharing statement

The data that support the findings of this study are available from the corresponding author (O Arrieta) upon e-mail request.

PDF download